PR Newswire Clinical TrialsOriginal article
Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
Phase 1ASC36Positive
AI Analysis
Summary
Ascletis initiated a Phase 1 study in the U.S. for ASC36, an oral amylin receptor peptide agonist for obesity treatment, demonstrating 6-8% oral bioavailability using the company's proprietary POTENT technology.
Clinical Trial Data
Phase
Phase 1
Importance:5/10
Sentiment:
0.50
obesitypeptideoralPhase 1POTENT technologyamylin receptor agonist
Read the original article
Published by PR Newswire Clinical Trials on September 8, 2026 10:10 AM